Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

A new study reveals that bariatric surgery results in significantly greater weight loss compared to popular GLP-1 drugs.

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...